secwatch.observer — SEC 8-K summary
======================================

Issuer:     Monte Rosa Therapeutics, Inc. (GLUE)
CIK:        0001826457
Form:       8-K
Filed at:   2026-01-09T23:59:59+00:00
Accession:  0001193125-26-009005
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Monte Rosa prices $300M public offering of common stock and pre-funded warrants
-------------------------------------------------------------------------------

- Offering of 11,125,000 shares at $24.00/share and pre-funded warrants for 1,375,000 shares at $23.9999 each.
- Gross proceeds ~$300M; estimated net ~$281.6M after discounts and expenses.
- Underwriters granted 30-day option to purchase up to 1,875,000 additional shares.
- Proceeds to fund MRT-8102 for atherosclerotic cardiovascular disease, QuEEN platform development, and working capital.
- Expects cash runway into 2029; closing expected on or about January 12, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1826457/000119312526009005/0001193125-26-009005-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1826457/000119312526009005/d36015d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-009005

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer